Journal of Vaccine Research 2024, Vol.14, No.4, 196-206 http://medscipublisher.com/index.php/jvr 197 monitoring is necessary to confirm the duration of immunity and identify any long-term safety concerns (Walsh et al., 2020; Furer et al., 2021; Sharif et al., 2021). This study comprehensively evaluates the long-term immunogenicity and safety profile of mRNA COVID-19 vaccines. By synthesizing data from various clinical trials and observational studies, it provides a detailed understanding of how these vaccines perform over extended periods. By examining the persistence of immune responses and the incidence of any long-term adverse events, this study aims to inform public health strategies and guide future vaccine development efforts. The scope of this research includes analyzing data from phase 1, 2, and 3 clinical trials, as well as real-world evidence from vaccinated populations, to present a holistic view of the long-term outcomes associated with mRNA COVID-19 vaccines. 2 Background on mRNA COVID-19 Vaccines 2.1 Mechanism of action and unique features of mRNA vaccines mRNA vaccines represent a novel approach to immunization, leveraging the body's cellular machinery to produce viral proteins that elicit an immune response. These vaccines use messenger RNA (mRNA) to encode the spike protein of the SARS-CoV-2 virus, which is the primary target for neutralizing antibodies. Once administered, the mRNA is taken up by host cells, which then translate the genetic information into the spike protein. This protein is subsequently presented on the cell surface, where it is recognized by the immune system, prompting the production of antibodies and the activation of T-cells (Heinz and Stiasny, 2021; Park et al., 2021). One of the unique features of mRNA vaccines is their rapid development and production timeline. Traditional vaccine platforms often require years of research and development, but mRNA vaccines were developed and authorized for emergency use within a year of the COVID-19 pandemic's onset. This expedited timeline is attributed to the synthetic nature of mRNA, which allows for quick design and manufacturing adjustments. Additionally, mRNA vaccines do not require live virus cultures, reducing the risk of contamination and enhancing safety (Heinz and Stiasny, 2021; Park et al., 2021). 2.2 Initial efficacy and safety data from clinical trials Initial clinical trials of mRNA COVID-19 vaccines, such as mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech), demonstrated high efficacy and a favorable safety profile. The phase 3 trial for mRNA-1273 enrolled over 30,000 participants and reported a vaccine efficacy of 94.1% in preventing symptomatic COVID-19. The trial also showed that the vaccine was effective across various subgroups, including older adults and those with pre-existing conditions. Common side effects included transient local and systemic reactions, such as pain at the injection site, fatigue, and mild fever, with serious adverse events being rare (Baden et al., 2021). Similarly, the BNT162b2 vaccine showed robust efficacy in its phase 1 trial, with participants developing neutralizing antibody titers comparable to or higher than those observed in convalescent serum samples. The vaccine was well-tolerated, with a lower incidence of systemic reactions in older adults compared to younger participants (Figure 1). These findings supported the advancement of BNT162b2 to phase 2 and 3 trials, where it continued to demonstrate strong immunogenicity and a good safety profile (Walsh et al., 2020). Walsh et al. (2020) revealed the occurrence of local reactions in participants of different age groups following administration of the BNT162b1 vaccine. The younger group (18-55 years) was more likely to experience pain at the injection site compared to the older group (65-85 years), especially after the second dose. However, the incidence of erythema and swelling reported by participants was low across all ages, and no severe reactions were observed. This indicates good local tolerability of the vaccine across different age groups, with injection site reactions primarily being mild to moderate. 2.3 Comparison with traditional vaccine platforms Compared to traditional vaccine platforms, mRNA vaccines offer several advantages. Traditional vaccines, such as inactivated or live-attenuated vaccines, require the cultivation of the virus, which can be time-consuming and poses biosafety risks. In contrast, mRNA vaccines are produced synthetically, allowing for rapid scalability and
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==